InMed Pharmaceuticals (INM) Change in Acquisitions & Divestments (2019 - 2026)
InMed Pharmaceuticals' (INM) quarterly Change in Acquisitions & Divestments came in at $16511.0 in Q1 2026, up 2.96% year-on-year from $16037.0 in Q1 2025, and up 293.21% quarter-over-quarter from $4199.0 in Q4 2025.
InMed Pharmaceuticals (INM) Change in Acquisitions & Divestments (2019 - 2026) Analysis & Trends
InMed Pharmaceuticals' Change in Acquisitions & Divestments history runs 6 years deep, the most recent figure standing at $16511.0 for Q1 2026.
- On a quarterly basis, Change in Acquisitions & Divestments rose 2.96% year-over-year to $16511.0 in Q1 2026; TTM through Mar 2026 was $43898.0, a 10.83% increase from a year earlier, with the FY2025 full-year figure at $42270.0, changed 0.45% from the prior year.
- Change in Acquisitions & Divestments climbed to $16511.0 in Q1 2026 per INM's latest filing, from $4199.0 in the prior quarter.
- Across five years, Change in Acquisitions & Divestments topped out at $21324.0 in Q3 2024 and bottomed at -$431.0 in Q2 2024.
- The 4-year median for Change in Acquisitions & Divestments is $16274.0 (2025), against an average of $12601.9.
- Biggest YoY gain for Change in Acquisitions & Divestments was 617.63% in 2025; the steepest drop was 24.34% in 2025.
- Year by year, Change in Acquisitions & Divestments stood at $21317.0 in 2023, then sank by 87.44% to $2678.0 in 2024, then jumped by 56.8% to $4199.0 in 2025, then jumped by 293.21% to $16511.0 in 2026.
- Per Business Quant, the three latest INM Change in Acquisitions & Divestments figures stand at $16511.0 (Q1 2026), $4199.0 (Q4 2025), and $20957.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | InMed Pharmaceuticals | 6.80 Mn | 1.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16,511.00 |
| Mar 31, 2026 | 16,511.00 |
| Dec 31, 2025 | 4,199.00 |
| Dec 31, 2025 | 4,199.00 |
| Sep 30, 2025 | 20,957.00 |
| Sep 30, 2025 | 20,957.00 |
| Jun 30, 2025 | 2,231.00 |
| Jun 30, 2025 | 2,231.00 |
| Mar 31, 2025 | 16,037.00 |
| Mar 31, 2025 | 16,037.00 |
| Dec 31, 2024 | 2,678.00 |
| Dec 31, 2024 | 2,678.00 |
| Sep 30, 2024 | 21,324.00 |
| Sep 30, 2024 | 21,324.00 |
| Jun 30, 2024 | -431.00 |
| Jun 30, 2024 | -431.00 |
| Mar 31, 2024 | 21,196.00 |
| Mar 31, 2024 | 21,196.00 |
| Sep 30, 2023 | 21,317.00 |
| Sep 30, 2023 | 21,317.00 |